Collaborative Approach to the Community
The ADCS serves as a scientific resource to support academic investigators, biotech companies, and other Principal Investigators (PIs) who have interventions that they wish to test in multicenter clinical trials that could benefit from collaboration with the ADCS. Over the last 5 years, the ADCS has evolved an interactive process whereby it can receive interest from PIs or other collaborators, to present to its Intervention Selection Committee (ISC) where a program review and proposed collaboration is undertaken with follow-up feedback to the presenters. This ADCS review follows an evaluation framework, developed by the ISC members, and benefits from the breadth of expertise of its members including preclinical, and clinical expertise in drug development as well as in lifestyle or multidomain interventions. The committee chair and Director of the ADCS, Dr. Howard Feldman or his delegate, provides feedback to those presenters after receiving back and collating reviews of the ISC. It is focused on next steps and sets up ongoing dialogue that can continue through the early development of the compounds or programs being presented.
To date, the ADCS ISC has advanced three programs from early discussions with to collaborations that include the ADCS undertaking POC multicenter clinical trials utilizing the network infrastructure of sites of the ADCS across the United States.
